Published in Biotech Business Week, March 31st, 2003
The group of outside experts told the U.S. Food and Drug Administration (FDA) that Merck's Emend cut down vomiting and nauseous episodes better than standard available treatments.
FDA, which rarely goes against the advice of its expert panels, is expected to meet with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.